###begin article-title 0
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 40 46 40 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 47 59 47 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 / MTS-1 </italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Cell cycle inhibitor and tumor suppressor gene p16 / MTS-1 has been reported to be altered in a variety of human tumors. The purpose of the study was to evaluate primary pancreatic ductal adenocarcinomas for potentially inactivating p16 alterations.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
We investigated the status of p16 gene by polymerase chain reaction (PCR), nonradioisotopic single strand conformation polymorphism (SSCP), DNA sequencing and hypermethylation analysis in 25 primary resected ductal adenocarcinomas. In addition, we investigated p16 protein expression in these cases by immunohistochemistry (IHC) using a monoclonal antibody clone (MS-887-PO).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Out of the 25 samples analyzed and compared to normal pancreatic control tissues, the overall frequency of p16 alterations was 80% (20/25). Aberrant promoter methylation was the most common mechanism of gene inactivation present in 52% (13/25) cases, followed by coding sequence mutations in 16% (4/25) cases and presumably homozygous deletion in 12% (3/25) cases. These genetic alterations correlated well with p16 protein expression as complete loss of p16 protein was found in 18 of 25 tumors (72%).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
These findings confirm that loss of p16 function could be involved in pancreatic cancer and may explain at least in part the aggressive behaviour of this tumor type.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 469 470 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Pancreatic cancer is a malignant neoplasm in the digestive tract the etiology of which is not known fully as yet. Recent advances in molecular oncology have provided explanations at the DNA level that multiple genetic changes contribute to pancreatic cancer development in which the p16 locus of tumor tissue is nearly always altered [1]. The p16 tumor suppressor gene located on 9p21 enodes a 16 KDa protein that acts as a cyclin dependent kinase (CDK) 4/6 inhibitor [2].
###end p 11
###begin p 12
###xml 67 72 67 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4b</sup>
###xml 77 82 77 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">waf1 </sup>
###xml 89 94 89 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">KIP1 </sup>
###xml 125 127 125 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
p16 belongs to an important group of proteins that includes the p15INK4b, p21waf1 and p27KIP1 which negatively regulate the G1 phase of cell cycle [2]. The p16 gene product binds to CDK4 and CDK6 inhibiting their interaction with cyclin D1. The inhibition of cyclin D1-CDK4/6 complex activity prevents retinoblastoma protein phosphorylation and release of E2F, leading to the inhibition of cell cycle in G1/S transition [3]. Genetic abnormalities inactivating the p16 gene thus confer a growth advantage to the cell contributing to tumorigenesis.
###end p 12
###begin p 13
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 139 142 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 142 148 142 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 775 779 775 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 903 921 903 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16, hMLH1 and VHL</italic>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Inactivating alterations of the gene have been commonly identified in a number of human malignancies [4,5]. In cancers, functional loss of p16INK4a occurs as a consequence of somatic mutations, homozygous and heterozygous deletions [6,7]. A high frequency of homozygous deletion and mutation of this gene have been detected in cell lines derived from different types of tumors (glioma, breast, lung, bladder and melanoma) [6,8] suggesting that p16 may play an important role in the regulation of cellular growth in the majority of cell types. However, homozygous deletions and somatic mutations are rarely observed in primary tumors with p16 genetic alterations [9,10]. On the other hand, denovo methylation has also been proposed to be an important alternative mechanism of p16 gene inactivation [11]. DNA hypermethylation can inhibit transcription of tumor suppressor genes and mismatch repair genes (p16, hMLH1 and VHL), providing an epigenetic mechanism of selection during tumorigenesis [11,12].
###end p 13
###begin p 14
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Abnormalities of tumor suppressor gene p16 have been reported in a variety of human tumors but less information is available regarding alterations of p16 in primary pancreatic ductal carcinoma than in pancreatic cancer derived cell lines and xenografts. There have been a few reports on the p16 alterations in tissue specimen of primary pancreatic ductal adenocarcinomas till date [13-17]. To provide further evidence that the cell cycle inhibitor p16 might be relevant for pancreatic tumorigenesis, we performed a comprehensive analysis of the mechanisms involved in p16 inactivation such as mutation, hypermethylation and homozygous deletion, in primary ductal adenocarcinomas.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Tissue samples
###end title 16
###begin p 17
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 50 57 <span type="species:ncbi:9606">patient</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
###xml 615 622 <span type="species:ncbi:9606">patient</span>
A written informed consent was obtained from each patient for inclusion in this study which was carried out after obtaining a formal approval from the Institute Ethics Committee. Pancreatic cancer tissues were obtained from 25 patients (15 males, 10 females) undergoing surgery for pancreatic cancer. Normal tissue away from the main tumor mass was taken as control. The age of these patients ranged from 27-78 years. According to the tumor, node, metastases classification of International Union against cancer [18], there were 2 patients with stage I, 8 patients with stage II, 14 patients with stage III and one patient with stage IV disease.
###end p 17
###begin p 18
Freshly removed pancreatic tissue samples were immediately fixed in 10% formalin for 24 hours and paraffin embedded. A section of each specimen was stained with hematoxylin and eosin and microscopically examined to confirm the diagnosis. In addition, fresh tissues for molecular analysis were frozen and stored at -80degreesC until use. One frozen section from each tissue subjected to molecular analysis was assessed histologically to ensure the presence of tumor and only those samples which contained >90% of tumor were included in the final analysis.
###end p 18
###begin title 19
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</italic>
###xml 39 44 39 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a</italic></sup>
Detection of homozygous deletion in p16INK4a
###end title 19
###begin p 20
###xml 296 297 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 334 338 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
Genomic DNA was isolated from the stored frozen tissue using the parallel RNA/DNA extraction kit (Qiagen, GmbH, Germany). PCR was performed using 100 ng template DNA and 10 pmol of each primer (Biobasic INC, Canada) in a volume of 50 mul containing 10 mM Tris HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 2.0 mM of each dNTPs and 1.5 units Taq polymerase (ROCHE, GmbH, Germany). The following primer pairs were used:
###end p 20
###begin p 21
Exon 1: 5' cggagagggggagaacagac 3' and 5' ctggatcggcctccgaccgtaac 3' 189 bp
###end p 21
###begin p 22
Exon 2: 5' tgagggaccttccgcggc 3' and 5' gtcatgatgatgggcagcgc 3' 307 bp
###end p 22
###begin p 23
Exon 3: 5' cacatccccgattgaaagaac 3' and 5' cagtgaatgaatgaaaatta 3' 489 bp
###end p 23
###begin p 24
These primers were designed by us based on their mRNA sequence available in the Genbank [Genbank: 4502748]. The PCR program was set for an initial denaturation at 95degreesC for 5 min, 35 cycles of denaturation at 95degreesC for 1 min, annealing at 55-56degreesC (depending on primer pair), for 1 min, extension at 72degreesC for 1 min and final extension at 72degreesC for 7 min. PCR reaction products were electrophoresed on a 1.5% agarose gel and were visualized under UV illuminator. Each time, a positive control (normal lymphocyte DNA) was included in the PCR reaction.
###end p 24
###begin title 25
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 28 34 28 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
Detection of mutation in p16INK4a gene by single strand conformation polymorphism (SSCP) analysis
###end title 25
###begin p 26
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
All samples were analysed for mutation in exon 1, 2 and 3 of p16 by SSCP [19] and DNA sequencing of the PCR products revealing a mobility shift.
###end p 26
###begin p 27
###xml 487 489 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
For SSCP analysis, 1 mul of each PCR product formed using the above mentioned PCR program and primers, was mixed with 9 mul SSCP loading buffer (98% v/v, formamide, 10 mM EDTA+0.05% Bromo-Phenol Blue+0.5% Xylene Cyanol) and incubated at 90degreesC for 5', followed by rapid cooling on ice. 10 mul of this mixture was loaded on a 6% acrylamide gel containing 1XTrisborate EDTA buffer. Following electrophoresis at 50 V at 4degreesC for 15-20 hrs, the gel was analysed by silver staining [20].
###end p 27
###begin p 28
The presence of bands with variant migration pattern was confirmed by repeating PCR-SSCP at least prior to extraction of band for DNA sequence analysis.
###end p 28
###begin title 29
DNA sequencing
###end title 29
###begin p 30
PCR products that revealed mobility shift on SSCP analysis were send for DNA sequencing. Automated sequencing reactions were carried out using Perkin Elmer Big Dye sequence Terminator Mix (ABI / PE, Foster, CA) as per manufacturer's instructions and sequenced on an ABI 377 sequencer.
###end p 30
###begin title 31
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 27 33 27 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
Methylation analysis of p16INK4a gene
###end title 31
###begin p 32
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
The methylation status of 5' CpG islands of p16 gene by bisulfite modification of DNA and Methylation Specific PCR (MS-PCR) was performed according to the method of Herman et al [21].
###end p 32
###begin p 33
Briefly, DNA (1 mug) in a volume of 50 mul was denatured by 0.2 M NaOH for 10' at 37degreesC, then 30 mul of 10 mM hydroquinone (Sigma, St. Louis, USA) & 520 mul of 3 M Na bisulfite, pH 5.0 (Sigma, St. Louis, USA), both freshly prepared were added to each sample. These were then incubated at 50degreesC/16 h. Modified DNA was purified using the wizard DNA purification Kit (Promega, Madison, WI, USA). Modification was completed by 0.3 M NaOH treatment for 5 min at room temperature, followed by ethanol precipitation, DNA was resuspended in distilled water and stored at -20degreesC.
###end p 33
###begin title 34
PCR amplification
###end title 34
###begin p 35
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 70 76 70 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
Sequences of primer pair (Biobasic, INC, Canada) used for MSPCR on p16INK4a gene were: unmodified or wild type primers (W), 5' cagaggtggggcggaccgc 3' and 5' cgggccgcggccgtgg 3'; methylated specific primers (M), 5' ttattagagggtggggcggatcgc 3' and 5' gaccccgaaccgcgaccgtaa 3'; unmethylated specific primers (U) 5' ttattagagggtggggtggattgt 3' and 5' caaccccaaaccacaaccataa 3'. PCR products identified by W, M and U primers were 140 bp, 150 bp and 151 bp respectively.
###end p 35
###begin p 36
###xml 102 104 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 402 406 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
The PCR mixture contained 1 x PCR buffer (16.6 mM ammonium sulphate / 67 mM Tris, pH 8.8 / 6.7 mM MgCl2 / 10 mM 2-mercaptoethanol) dNTPs (each at 2 mM), Primers (100 pmol) and bisulfite treated DNA (~50 ng) or unmodified DNA (50-100 ng) in a final volume of 50 mul. PCR specific for unmodified DNA also included 5% DMSO. Reactions were hot started 95degreesC for 5' before the addition of 1.5 units of Taq polymerase (ROCHE, GmbH, Germany).
###end p 36
###begin p 37
Amplification was carried out in the following conditions, 35 cycles at 95degreesC (30 sec), 60-65degreesC (depending on the type of primer pair used) (30 sec), 72degreesC (30 sec) followed by a final 5 min extension at 72degreesC. Each PCR product was loaded onto a 2% agarose gel, stained with ethidium bromide and visualized under UV illuminator. DNA from Raji cell line was used as a positive control for methylated alleles of this gene. DNA from normal lymphocyte was used as the control for unmethylated alleles.
###end p 37
###begin title 38
Immunohistochemistry
###end title 38
###begin p 39
###xml 291 292 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 295 292 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Immunohistochemical detection was performed according to the avidin biotin complex method using the ABC staining kit (Santa Cruz Biotech INC., CA, USA). In brief, 5 mum sections were cut from formalin fixed, paraffin embedded tissue specimens. After treatment with blocking solution (0.03% H2O2 in methanol) to block endogenous peroxidase activity, the antigenic sites were unmasked by means of 3 cycles of 5 minutes microwave irradiation in 10 mM citrate buffer (pH 6.0). Sections were then incubated with the primary antibodies (Neomarkers, Fremont, USA) against p16 (clone MS-887-PO) used at 1:20 dilution, for 2 hours at room temperature. Sections were further incubated with the secondary biotinylated antibody followed by treatment with ABC reagent. The slides were developed using 3-3' diaminobenzidine as the chromogen and counterstained with hematoxylin followed by mounting with DPX.
###end p 39
###begin p 40
The IHC results were scored by taking percentage positivity and intensity of staining into account. An intensity score of 0 = No staining, 1 = weak positivity; 2 = moderate positivity & 3 = strong positivity was given.
###end p 40
###begin title 41
Statistical analysis
###end title 41
###begin p 42
The following statistical tests were applied to analyze the data:
###end p 42
###begin p 43
Wilcoxon Signed Rank Test, Chi Square Test and Pearson Correlation Coefficient Test. A probability value of less than 0.05 was considered to be significant.
###end p 43
###begin title 44
Results
###end title 44
###begin p 45
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Paired normal and tumor DNA from 25 patients with pancreatic cancer were examined for the occurrence of p16 genetic alterations.
###end p 45
###begin title 46
Homozygous deletion
###end title 46
###begin p 47
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
We separately amplified exon 1, 2 & 3 of p16 using specific primers for homozygous deletion and for SSCP analysis of PCR products. In 3 out of 25 (12%) tumors, we failed to amplify exon 1, 2 and 3 whereas these three exons could be amplified from the corresponding normal pancreatic tissue (Fig 1). Hence, in these three cases there was presumably a homozygous deletion of the p16 gene.
###end p 47
###begin title 48
SSCP analysis
###end title 48
###begin p 49
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
To screen for mutation in p16 gene, exon 1, 2 and 3 were analysed by PCR-SSCP. 5 out of 25 cases analysed showed evidence for p16 mutation (exon1, one case; exon 2, four cases) (Fig 2). No mobility shift of exon-3 was found in any sample. DNA samples showing electrophoretic band shift mobility were reamplified and the product purified and used directly for sequencing. DNA sequence analysis of these abnormally migrating SSCP fragment revealed point mutations in 4 out of 5 cases (3 transversions and 1 missense mutation) (Fig. 3). Table 1 summarizes the SSCP and DNA sequencing data for these.
###end p 49
###begin title 50
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
Methylation analysis of p16
###end title 50
###begin p 51
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 25 31 25 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
Methylation status of p16INK4a gene was evaluated in 25 tumors. A total of 13 (52%) samples showed evidence of promoter methylation. In 11 out of these 13 cases, the gene was completely methylated while in the other 2 cases the gene was partially methylated (Fig. 4).
###end p 51
###begin title 52
p16 immunohistochemistry
###end title 52
###begin p 53
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Loss of p16 protein expression was noted in 18 out of 25 tumors as determined by immunohistochemistry. However, 7 out of 25 (28%) ductal adenocarcinomas stained positive for p16 with weak/focal p16 nuclear staining in 4 and moderate positivity in 3 cases (Fig. 5A). In normal pancreas, p16 nuclear positivity was noted in islets of Langerhans with scattered non-specific cytoplasmic positivity in ductal and acinar cells (Fig. 5B).
###end p 53
###begin title 54
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Comparison of p16 gene alterations to p16 protein expression
###end title 54
###begin p 55
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
The p16 gene alterations were compared to the p16 protein expression and the results are tabulated in Table 2. In the 18 adenocarcinomas negative for p16 expression, 11 had methylation of the promoter region. The p16 gene was deleted in 3 cases with mutations detected in 2 additional cases. However, two tumors negative for p16 expression did not reveal any of the genetic alterations.
###end p 55
###begin title 56
Statistical analysis
###end title 56
###begin p 57
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
These genetic alterations showed a significant correlation with the p16 protein expression (Pearson Correlation Coefficient Test and Chi Square Test, p < 0.01). However, no correlation was found between p16 gene alterations (mutation, deletion and hypermethylation) and age, TNM staging and histological differentiation (Wilcoxon Signed Rank Test and Chi Square Test, p > 0.05).
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rb / p16 </italic>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 222 228 222 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
###xml 255 258 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rb </italic>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
The Rb / p16 tumor suppressive pathway can be abrogated in tumors by inactivation of any of the several members of the pathway [22,23]. For pancreatic carcinoma, this disruption is caused exclusively by inactivation of p16INK4a gene and, only rarely, the Rb gene [24,25]. Inactivation of p16 gene occurs through intragenic mutation, homozygous deletion and methylation associated transcriptional silencing. In the present study, all known mechanisms of p16 inactivation were analysed and we found evidence of p16 inactivation in a high proportion (80%) of the pancreatic tumors examined.
###end p 59
###begin p 60
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1201 1203 1201 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1518 1522 1516 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 1532 1534 1530 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1749 1751 1747 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2395 2397 2393 2395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2398 2400 2396 2398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Most of the previous studies regarding pancreatic cancer have reported an elevated frequency of p16 gene alterations in pancreatic cancer derived cell line and xenografts [7,13,26,27]. There have been a few reports on the p16 alterations in tissue specimen of primary pancreatic ductal adenocarcinomas. Our report is the sixth such study and the first from India. A comparison of the result of all the reports with the present study is shown in Table 3. Homozygous deletion could not be detected in two studies by Gerdes et al [14] and Ohtsubo et al [15], but were observed in 35% cases in the study by Zhonghua et al [16]. In our study, we were unable to amplify the p16 exons 1-3 in 12% cases presumably indicating homozygous deletion which is in good agreement with 10% deletion frequency reported by Huang et al [13]. We identified mutation in 4 out of 25 (16%) cases which is consistent with 15% mutation frequency reported by Ohtsubo et al [15]. However, this frequency is lower than 22.5% reported by Gerdes et al [14]. Also, the frequency of mutation was higher in exon 2 than exon 1 (3 cases in exon 2 compared with 1 case for exon 1). This result is consistent with the previous reports [13,14]. Of the 4 points mutations reported here, 3 were transversions and 1 was a missense mutation. Importantly, one out of these four mutations (glutamine --> valine at codon 88) was located in the ankyrin repeat III in a highly conserved region believed to form the CDK binding cleft and may have resulted in loss of p16 function [28]. Out of the remaining three mutations, one was in ankyrin repeat I and two others were in ankyrin repeat IV. None of these mutations involved the conserved amino acid and hence may not be crucial to p16 function [28]. On the other hand, two of these mutations resulted in a loss of p16 protein expression and so, it may be postulated that they could have affected the stability and half life of the mRNA or protein. This postulation needs confirmation by further experimental approaches. In 2 out of 18 tumors negative for p16 protein expression, we were unable to detect any genetic alteration in the form of deletion, mutation or promoter hypermethylation. However, presence of a mutation is not completely excluded, as we used PCR-SSCP as a screening tool and it is known from the published studies that this technique detects only about 70% of mutations [19,29].
###end p 60
###begin p 61
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 782 786 782 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 840 844 840 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 993 997 993 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1045 1053 <span type="species:ncbi:9606">patients</span>
###xml 1109 1117 <span type="species:ncbi:9606">patients</span>
We have observed hypermethylation to be a major mechanism of p16 inactivation. This frequency is higher than the 27% frequency reported by Gerdes et al [14] and Fukushima et al [30]. Other studies report and even lower frequency of 15% and 3.3% [15,17]. The later study was however performed on microdissected tissue samples using restriction enzyme analysis in contrast to our study on fresh samples using MSPCR. Another explanation for the observed differences in the methylation frequencies could be differences in the ethnicity of the population studied and the role of unknown environmental factors. Such a difference in the methylation profile is reported in the context of hepatocellular carcinomas by Shen et al [31]. In pancreatic cancer cell lines also, the prevalence of p16 promoter methylation has ranged from 18%-38% [27,32]. p16 promoter methylation has also been detected in pancreatic intraductal neoplasia adjacent to pancreatic cancer [28,33,34]. Moreover, the detection of p16 promoter methylation in the pancreatic fluid of patients with pancreatic cancer but not in chronic pancreatitis patients has suggested its potential role as a diagnostic marker in the differentiation of benign and malignant pancreatic disease [35].
###end p 61
###begin p 62
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 867 871 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
Most of the previous studies which have correlated p16 alterations to survival data are limited by the fact that a comprehensive analysis of the p16 genetic alterations is lacking. Bartsch et al [36] found reduced survival in patients with p16 mutations but this study did include the analysis of p16 inactivation by homozygous deletions. Hu et al [37], found longer survival in patients with immunohistochemically p16 positive tumors compared with p16-negative ones, but this difference was not significant. Naka et al [38], identified a significantly longer survival in IHC p16 positive tumors, but the analysis of gene mutations was not examined in these studies. The association of p16 alterations with worse prognosis has also been reported by Gerdes et al [14] and Ohtsubo et al [15]. In the present analysis, although correlation to survival was not possible, p16 alterations did not show any association with the stage or histological grade of the tumor.
###end p 62
###begin title 63
Conclusion
###end title 63
###begin p 64
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
Overall, our findings support the observations that p16 / MTS-1 gene alterations play a key role in dysregulated growth of pancreatic cancer and that methylation of the promoter is an important mechanism of its inactivation in Indian patients with pancreatic ductal adenocarcinoma.
###end p 64
###begin title 65
Competing interests
###end title 65
###begin p 66
The author(s) declare that they have no competing interests.
###end p 66
###begin title 67
Authors' contributions
###end title 67
###begin p 68
###xml 345 352 <span type="species:ncbi:9606">patient</span>
SJ carried out the molecular genetic studies and drafted the manuscript. SR participated in its design, coordination and helped to draft the manuscript. MS did DNA sequencing part of the study and coordinated the study. DRB did immunohistochemical part of the study. WJ provided the tissue samples and all the clinical information regarding the patient. All authors have read and approved the final manuscript.
###end p 68
###begin title 69
Pre-publication history
###end title 69
###begin p 70
The pre-publication history for this paper can be accessed here:
###end p 70
###begin p 71

###end p 71
###begin article-title 72
Molecular pathways of pancreatic carcinogenesis
###end article-title 72
###begin article-title 73
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D/CDK4</italic>
A new regulatory motif in cell cycle control causing specific inhibition of cycling D/CDK4
###end article-title 73
###begin article-title 74
The retinoblastoma protein and the regulation of cell cycling
###end article-title 74
###begin article-title 75
###xml 15 27 15 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2 (p16) </italic>
Alterations of CDKN2 (p16) in Non-small cell lung cancer
###end article-title 75
###begin article-title 76
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Alteration of p16 gene in-testicular, ovarian and endometrial malignancies
###end article-title 76
###begin article-title 77
A cell cycle regulator potentially involved in genesis of many tumor types
###end article-title 77
###begin article-title 78
###xml 55 66 55 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 (MTSI) </italic>
Frequent somatic mutations and homozygous deletions of p16 (MTSI) gene in pancreatic adenocarcinoma
###end article-title 78
###begin article-title 79
###xml 65 70 <span type="species:ncbi:9606">human</span>
Deletion of cyclin dependent kinase-4 inhibitor gene in multiple human cancers
###end article-title 79
###begin article-title 80
###xml 34 43 34 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16/MTS1 </italic>
###xml 46 51 <span type="species:ncbi:9606">human</span>
In frequent somatic alteration of p16/MTS1 in human primary superficial bladder cancer
###end article-title 80
###begin article-title 81
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2 </italic>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Compilation of somatic mutation of CDKN2 gene in human cancers: non random distribution of base substitutions
###end article-title 81
###begin article-title 82
###xml 91 110 91 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 / CDKN2 / MTS1 </italic>
###xml 113 118 <span type="species:ncbi:9606">human</span>
5' CpG island methylation is associated with transcriptional silencing of tumor suppressor p16 / CDKN2 / MTS1 in human cancers
###end article-title 82
###begin article-title 83
Alterations in DNA methylation : a fundamental aspect of neoplasia
###end article-title 83
###begin article-title 84
###xml 38 48 38 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16/MTS-1 </italic>
###xml 73 78 <span type="species:ncbi:9606">human</span>
Deletion and mutation analysis of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic carcinoma reveals higher frequency of abnormalities in tumor derived cell lines than in primary ductal adenocarcinomas
###end article-title 84
###begin article-title 85
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 3 9 3 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</italic>
###xml 88 93 88 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a</italic></sup>
###xml 109 111 109 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rb</italic>
p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2 and Rb
###end article-title 85
###begin article-title 86
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Abnormalities of tumor suppressor gene p16 in carcinoma: Immunohistochemical and genetic findings compared with clinicopathological parameters
###end article-title 86
###begin article-title 87
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Study on the relationship on alterations and expression of p16 gene to pancreatic carcinoma
###end article-title 87
###begin article-title 88
Pancreatic tumors: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine non-ductal or endocrine tumorigenesis
###end article-title 88
###begin article-title 89
PCR-SSCP: a simple & sensitive method for detection of mutation in the genomic DNA
###end article-title 89
###begin article-title 90
Fast and sensitive silver staining of DNA in polyacylamide gels
###end article-title 90
###begin article-title 91
Methylation specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 91
###begin article-title 92
###xml 59 64 <span type="species:ncbi:9606">human</span>
Altered expansion of cyclin D1 and retinoblastoma genes in human osophageal cancer
###end article-title 92
###begin article-title 93
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
CDK4 amplification is an alternative mechanism of p16 gene homozygous deletion in glioma cell lines
###end article-title 93
###begin article-title 94
Allelotype of pancreatic adenocarcinoma
###end article-title 94
###begin article-title 95
###xml 68 73 <span type="species:ncbi:9606">human</span>
Abnormalities of the RB1 and DCC tumor suppressor gene: uncommon in human pancreatic adenocarcinoma
###end article-title 95
###begin article-title 96
Tumor suppressive pathways in pancreatic carcinoma
###end article-title 96
###begin article-title 97
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rb/p16 </italic>
Abrogation of the Rb/p16 tumor suppressor pathway in virtually all pancreatic carcinomas
###end article-title 97
###begin article-title 98
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 40 46 40 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
Biologic and biochemical analysis of p16INK4a mutations from primary tumors
###end article-title 98
###begin article-title 99
Sensitivity of single strand conformation polymorphisms and heteroduplex method for mutation detection in the cystic fibrosis gene
###end article-title 99
###begin article-title 100
Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma
###end article-title 100
###begin article-title 101
###xml 47 52 <span type="species:ncbi:9606">human</span>
DNA methylation and environmental exposures in human hepatocellular carcinoma
###end article-title 101
###begin article-title 102
Hypermethylation of multiple genes in pancreatic adenocarcinoma
###end article-title 102
###begin article-title 103
###xml 16 25 16 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16INK4a </italic>
Inactivation of p16INK4a tumor suppressor gene in duct lesions: loss of intranuclear expression
###end article-title 103
###begin article-title 104
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 3 9 3 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
p16INK4a alteration in chronic pancreatitis - indicator for high risk lesions for pancreatic cancer
###end article-title 104
###begin article-title 105
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14ARF </italic>
###xml 33 42 33 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16INK4a </italic>
Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions
###end article-title 105
###begin article-title 106
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation
###end article-title 106
###begin article-title 107
Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma
###end article-title 107
###begin article-title 108
###xml 9 17 9 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16INK4 </italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer
###end article-title 108
###begin title 109
Figures and Tables
###end title 109
###begin p 110
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
PCR analysis of p16 exon 1, 2 & 3 in normal pancreas and pancreatic tumor. M: Molecular weight marker; N: Normal Pancreas; T: Pancreatic Cancer.
###end p 110
###begin p 111
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
PCR-SSCP analysis of p16 mutations in pancreatic cancer samples. Arrows indicates bands with a mobility shift.
###end p 111
###begin p 112
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Automated DNA sequencing results to determine point mutations in p16 exon 1 and 2.
###end p 112
###begin p 113
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 159 162 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
Methylation specific PCR of p16 gene in normal pancreas and in pancreatic cancer. M: PCR with primers for methylated p16. U: PCR with primers for unmethylated p16. NL : Normal Lymphocyte DNA used as a negative control for methylation. Raji: Cell line DNA used as a positive control for methylation. MW: Molecular weight marker.
###end p 113
###begin p 114
Immunohistochemical staining of p16 in representative cases of (A) pancreatic cancer (B) Normal pancreas (original magnification x200).
###end p 114
###begin p 115
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
p16 sequence changes in pancreatic cancer.
###end p 115
###begin p 116
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Comparison of p16 protein expression to the p16 gene alterations.
###end p 116
###begin p 117
+ / + : Completely methylated
###end p 117
###begin p 118
- / - : Unmethylated
###end p 118
###begin p 119
+ / - : Partially methylated
###end p 119
###begin p 120
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16 </italic>
Studies showing p16 alterations in tissue specimen of primary pancreatic ductal adenocarcinomas.
###end p 120
###begin p 121
NE: Not Examined; ND: Not Detected
###end p 121

